Media headlines about Cepheid (NASDAQ:CPHD) have been trending somewhat positive recently, Accern reports. The research group identifies negative and positive news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cepheid earned a coverage optimism score of 0.12 on Accern’s scale. Accern also assigned headlines about the scientific and technical instruments company an impact score of 49.7870703451747 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Shares of Cepheid (CPHD) remained flat at $52.95 during midday trading on Tuesday. The company has a 50-day moving average of $52.75 and a 200 day moving average of $38.36. Cepheid has a 12 month low of $25.09 and a 12 month high of $53.91.

WARNING: “Cepheid (CPHD) Given Daily News Impact Rating of 0.12” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at

About Cepheid

Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company’s systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures.

Insider Buying and Selling by Quarter for Cepheid (NASDAQ:CPHD)

Receive News & Ratings for Cepheid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cepheid and related companies with Analyst Ratings Network's FREE daily email newsletter.